Genetic markers associated with resistance to radioiodine therapy in thyroid cancer patients: Prospective cohort study

Author:

Denisenko Natalia P.ORCID,Shuev Grigorij N.ORCID,Mukhamadiev Reis H.ORCID,Perfilieva Oksana M.,Kazakov Ruslan E.ORCID,Kachanova Anastasia A.ORCID,Milyutina Olga I.ORCID,Konenkova Olga V.ORCID,Ryzhkin Sergey A.ORCID,Ivashchenko Dmitriy V.ORCID,Bure Irina V.ORCID,Kirienko Sergey L.,Zhmaeva Elena M.,Mirzaev Karin B.ORCID,Ametov Alexander S.ORCID,Poddubnaya Irina V.ORCID,Sychev Dmitry A.ORCID

Abstract

Background. The indication for radiotherapy in oncological practice are metastases of differentiated thyroid cancer after thyroidectomy, the presence of distant metastases, or stage N1b, or negative dynamics of blood thyroglobulin levels after thyroidectomy for thyroid cancer. The mechanism of action of radiotherapy is based on provoking double-stranded DNA breaks. It is important to study the role of polymorphisms of NFKB1, ATM, ATG16L2 and ATG10 genes, products of which are involved in the processes of DNA damage response pathway and autophagy, in the formation of resistance to radioiodine therapy of thyroid cancer patients. Aim. To examine the association between NFKB1, ATM, ATG16L2 and ATG10 polymorphisms and resistance to radioiodine therapy in thyroid cancer patients. Materials and methods. The study included 181 patients (37 men, 144 women; mean age 53.515.7 years) with histologically confirmed thyroid cancer and a history of thyroidectomy who received radioiodine therapy. Carriage of single-nucleotide polymorphisms (rs230493) NFKB1, (rs11212570) ATM, (rs10898880) ATG16L2 and (rs10514231, rs1864183, rs4703533) ATG10 was determined by real-time PCR using TaqMan kits. Results. Among 181 patients, resistance to radioiodine therapy was observed in 11 (6.1%) cases. No significant associations between the individual polymorphisms and resistance to radioiodine therapy were obtained, p0.05. Haplotype analysis showed that carriage of the C-C ATG10 rs10514231-rs1864183 haplotype was associated with an increased risk of developing resistance to radioiodine therapy, p=0.04. Conclusion. Further studies on large samples of radioiodine therapy-resistant patients using whole-genome sequencing methods are required to specify the role of genetic factors in the response to 131I therapy.

Publisher

Consilium Medicum

Subject

Cancer Research,Oncology

Reference27 articles.

1. The Benefits and Risks of I-131 Therapy in Patients with Well-Differentiated Thyroid Cancer

2. Клинические рекомендации «Дифференцированный рак щитовидной железы» (утв. Минздравом России, 2020 г.). Режим доступа: https://cr.minzdrav.gov.ru/recomend/329_1. Ссылка активна на 16.04.2022 [Clinical recommendations: differentiated thyroid cancer (approved by the Ministry of Health of Russia, 2020). Available at: https://cr.minzdrav.gov.ru/recomend/329_1. Accessed: 16.04.2022 (in Russian)].

3. The DNA-damage response in human biology and disease

4. DNA damage response in nephrotoxic and ischemic kidney injury

5. DNA Damage Sensing by the ATM and ATR Kinases

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3